TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Renal clearance of maraviroc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Colectomy within 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Perception of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of control during eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MRI sensitivity for detecting contralateral cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PEM sensitivity for detecting contralateral cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive predictive value of PEM and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major hypoglycemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial plasma glucose increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximum intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cervical spine motion at occiput-C1 segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine motion at C1-C2 segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine motion at C2-C5 segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms and Limitations in Physical Function of the PADQOL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in ICQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in PPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unbound plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 4/5 infections
Endpoint domain: Adverse events/effects
Primary endpoint: grade 3/4 pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: prolonged cytopenias for >60 days
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urge to smoke
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinically‐indicated target lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: target vessel myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: isokinetic muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women delivered within 14 days
Endpoint domain: Mortality/survival
Primary endpoint: Opioid discontinuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCP follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in verbal fluency test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone turnover markers (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle fatigue for lower back muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lumbar range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall satisfaction with hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: all-injuries risk
Endpoint domain: Adverse events/effects
Primary endpoint: soft-tissue injury risk
Endpoint domain: Adverse events/effects
Primary endpoint: bone injury risk
Endpoint domain: Adverse events/effects
Primary endpoint: dialysis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improved shoulder strength for internal rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in frequency of extreme shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour esophageal acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Work during 5 min cycle time-trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal rate of heart rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in voids per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: axillary recurrence at 56 months
Endpoint domain: Mortality/survival
Primary endpoint: plasma indinavir concentrations at 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clarithromycin AUC(0‐12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 14‐hydroxyclarithromycin AUC(0‐12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypotensive events
Endpoint domain: Adverse events/effects
Primary endpoint: need for vasoactive medication
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of airway bacterial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of MDR colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Non-fatal/non-MACE events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative hospitalisation days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Chair rise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-RM for leg extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ‐log PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of atelectases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: minutes of moderate/vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Yale‐Brown Obsessive Compulsive Scale Modified for BDD (BDD‐YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings from dyspepsia treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maintaining MAP >60 mmHg without norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative net fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days alive and free of ventilation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Response (CR) rates at 24 and 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Postoperative Nausea and Vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inaccurate dietary reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differentiation of MG patients from healthy controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct adherence to ADL items
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-reported itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: BOLD activation in primary gustatory cortex and amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rated sucrose liking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinks/drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive attention required while walking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement on the Oswestry scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the VAS for back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for antegrade CFA puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications (haematomas)
Endpoint domain: Adverse events/effects
Primary endpoint: Tidal volume variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central apneas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients remaining on infliximab after 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of grade 3 and 4 diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: median loss in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant difference in SELs from placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment time after 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auscultation score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual-analog-scale score for sputum cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the ONH algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the ONH algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success (PGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean HECSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk perception of ASCVD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to consider therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: composite endpoint of cardiovascular death, myocardial infarction, and ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Thrombolysis In Myocardial Infarction major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Intensity Difference at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: monocyte production of TNFalpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: likelihood to use program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of major or minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: H3K56ac levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FBS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV acquisition risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: lower intake levels of fried foods, HFSS foods, and sodas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: immediate posttreatment cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increment rate of AIIc%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: high-risk pattern of sexual behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing levels at 500 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WDS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of complete and partial hearing recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: elevation in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidences of combined cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxidative stress markers (thiobarbituric acid reactive substances)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke, myocardial infarction, or death
Endpoint domain: Mortality/survival
Primary endpoint: Area under the drug plasma concentration-time curve at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-operation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative logMAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retronasal olfactory function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Clinical Global Impression (CGI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of stroke/systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Risk of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: fasting plasma glucose changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial plasma glucose AUC(0‐2h) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Negative test reactions to histamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: length of in-hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Flexion and supination strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal contribution to overjet correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxilla forward movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in clinically important cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total effective rate of neurological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activities of daily living (ADL) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rescue fentanyl use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numerical rating scale (NRS) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory block level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese Pittsburgh Sleep Quality Index global score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Short‐form 12 mental health component
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in glycated haemoglobin (HbA(1c))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression to permanent insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative bleeding within first 12-h period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative blood loss within 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Statistically significant difference in SEF90% and BIS between unconscious and conscious sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periorbital edema ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ecchymosis ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-week stone-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complications reported
Endpoint domain: Adverse events/effects
Primary endpoint: pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: spike frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spike amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of preference matches
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in urinary TGF-beta1 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean valgus deviation of the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per person per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall short term cost to the health service
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cost per 1% reduction in risk
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge on fruit and vegetable recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral improvements in fruit and vegetable consumption
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: patient-reported pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ICD Rx for fast VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post‐traumatic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of the injured side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering in serum endotoxin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sun Protection Factor (SPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory performance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preventive practices scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decreased plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in subjective plaque‐associated erectile dysfunction (quality of erection)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in 24-hour urinary sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: T2* response of contrast-enhancing brain tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of functional coagulopathy parameters (R and MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nipple elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement to postpreparation stage
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in total fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived health state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: h-FABP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean healing duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kerr's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent in hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial smooth muscle-dependent dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes